Anixa is focused on the treatment and prevention of cancer.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology.  Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.


Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Vaccines

Breast Cancer Vaccine

We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

Read More...

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

Read More...

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change